Table 4: Correlations between depressive symptoms and clinical assessments in RA subjects.

()Pseudo AICcCoefficientOdds ratio (95% CI) value

Characteristics
Disease duration (years), mean ± SD17.56 ± 11.480.252461.64−0.0400.96 (0.88–1.05)0.401
BMI, mean ± SD26.46 ± 5.490.144557.560.0281.03 (1.01–1.04)< 0.001
Pain score, median60.411527.310.1141.12 (1.08–1.16)< 0.001
Smoking, number (%)0 (0)< 0.001570.11−0.0290.97 (0.77–1.22)0.806
Drinking, number (%)13 (16)0.014569.01−0.1290.88 (0.69–1.11)0.290
Physical activity, number (%)13 (16)0.256546.22−0.6680.51 (0.38–0.68)< 0.001
Biologic medication, number (%)42 (51)0.027570.09−0.0820.92 (0.73–1.18)0.503
Classic medication, number (%)55 (67)0.030569.89−0.0620.94 (0.75–1.19)0.601
Disease activity (patient), mean ± SD54.04 ± 30.160.880426.210.0021.01 (1.01–1.02)< 0.001
Disease activity (doctor), mean ± SD35.44 ± 27.030.890419.810.0131.01 (1.01–1.02)< 0.001
Laboratory
Sedementation velocity, mean ± SD26.59 ± 22.270.834448.130.0101.01 (1.01–1.01)< 0.001
C-reactive protein, mean ± SD11.11 ± 17.430.778468.090.0061.01 (1.00-1.01)0.007
DAS28, mean ± SD5.04 ± 5.650.830449.810.0381.04 (1.02–1.05)< 0.001
Brain leukocytes, mean ± SD8.09 ± 3.400.707484.340.0101.01 (0.98–1.04)0.425
Brain lymphocytes, mean ± SD27.10 ± 9.840.713482.76−0.0070.99 (0.98–1.00)0.139
Anti-dsDNA, mean ± SD10.66 ± 5.300.999248.280.0171.02 (1.00-1.04)0.069